Table 2.
Serum Ca, PO4, and PTH levels and dosages of PO4 binders and alphacalcidol in patients and control subjectsa
| Parameter | Patients (n = 61)
|
Control Subjects (n = 40) | Pb | |
|---|---|---|---|---|
| Exposure from the Onset of Stage 4 CKD | Values at the Time of Study | |||
| Serum PO4 level (mmol/L; mean ± SD) | 1.5 ± 0.7c | 1.4 ± 0.5 | 0.9 ± 0.3 | 0.007 |
| Serum Ca (albumin adjusted; mmol/L; mean ± SD) | 2.4 ± 0.1c | 2.4 ± 0.0 | 2.3 ± 0.2 | 0.190 |
| Serum Ca-PO4 product (mmol2/L2; mean ± SD) | 4.2 ± 0.9c | 4.3 ± 0.4 | 3.3 ± 0.3 | 0.002 |
| Serum iPTH (fold ULN; mean ± SD) | 1.8 ± 1.3c | 1.6 ± 0.9 | ND | – |
| PO4 binders | ||||
| Patients on Ca-based PO4 binders (n [%]) | NA | 52 (88) | – | – |
| Patients on sevelamer ± Ca-based PO4 binders (n [%]) | 9 (12) | – | ||
| Intake of elemental Ca from PO4 binders (g/kg per yr; mean ± SD) | 31.9 ± 11.8d | NA | 0 | – |
| dosage (mg/day; mean ± SD) | NA | 1828 ± 52 | 0 | – |
| Alphacalcidol (μ /kg per yr; mean ± SD) | 19.2 ± 7.3d | NA | 0 | – |
| dosage (μ g/d; mean ± SD) | NA | 0.89 ± 0.3 | 0 | – |
| Parathyroidectomy | 0 | 0 | 0 | – |
a
ND, not done.
b
Compares values at the time of the study between patients and control subjects.
c
All biochemical values in this column are expressed as mean time-averaged values from the onset of stage 4 CKD.
d
The dosage of elemental calcium intake from PO4 binders and the alphacalcidol dosage are expressed as the cumulative intake from stage 4 CKD and standardized per year of exposure to account for the varied duration since onset of stage 4 CKD.